查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190481

C 反應蛋白檢測市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

C-Reactive Protein Testing Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

C 反應蛋白 (CRP) 檢測市場預計在預測期內（2022 年至 2027 年）以 1.8% 的複合年增長率增長。

COVID-19 正在以前所未有的方式影響醫療保健和診斷行業。 例如，根據 2020 年 5 月發表在《臨床微生物學和抗菌藥物年鑑》上的一項題為“血漿 CRP 水平與 COVID-19 的嚴重程度正相關”的研究，血漿 CRP 水平與 COVID-19 肺炎的嚴重程度相關。被揭露相關。 這一發現可能有助於區分輕度 COVID-19 肺炎患者和中重度 COVID-19 肺炎患者。 這是嚴重疾病的早期預警信號，可以讓醫生更好地對患者進行分層，以便將其轉移到重症監護病房。 CRP 檢測對 COVID-19 感染患者分層的重要性將導致對 CRP 檢測的需求增加，從而影響大流行期間的市場增長。

推動 C 反應蛋白檢測市場增長的主要因素是炎症性疾病、糖尿病、癌症患病率上升、全球女性子宮內膜異位症發病率上升，其中包括對技術進步的資金投入增加以及點-護理設備。

根據美國疾病控制與預防中心發布並於 2022 年 7 月更新的數據，美國約有 2010 萬 20 歲及以上的成年人患有冠狀動脈疾病。. 另據報導，美國每年約有 805,000 人心髒病發作。 心血管疾病患病率上升將導致更多地採用 CRP 檢測來識別與心血管疾病相關的風險，從而推動市場增長。

此外，越來越多的床旁 CRP 檢測產品發布有望促進 CRP 檢測市場的增長。 例如，2020 年 5 月，ProciseDx 為 Procise CRP 測試提交了 510k。 該測試是利用 ProciseDx 的 FRET（熒光共振能量轉移）護理點設備進行的，這是一種在胃腸道治療中廣泛使用的炎症標記物。

因此，預計在預測期內，心血管疾病患病率上升和床旁 CRP 檢測產品發布數量增加等因素將推動該市場的增長。 另一方面，缺乏公眾意識和替代療法的可用性預計會阻礙市場的增長。

主要市場趨勢

在預測期內，□聯免疫吸附測定 (ELISA) 部分預計將佔據很大的市場份額

□聯免疫吸附測定 (ELISA) 部分預計將在 C 反應蛋白檢測市場的測定類型中佔據很大份額。 癌症患病率上升、COVID-19等傳染病數量增加、ELISA 測試商業化合作夥伴關係激增以及產品發布激增等因素將在預測期內推動該細分市場的增長。

根據 Globocan 2020，2020 年全球將有 1930 萬癌症患者和 1000 萬癌症死亡病例。 由於 ELISA 測試是早期檢測癌症的有用方法，因此有望在全球範圍內引入用於癌症檢測並引領該領域的發展。

此外，提供相同測試的設施的建立也有望促進市場的增長。 例如，2021 年 6 月，Trivitron Healthcare 推出了 COVID-19 診斷移動實驗室，以促進印度城市、農村和偏遠地區的 COVID-19 診斷。 這個本土實驗室提供諸如 D-二聚體、CRP 和 IL-6 等炎症標誌物的 CLIA/Elisa 測試、RT-PCR 測試、快速抗原測試、CLIA/Elisa 抗體測試 IgG 和 IgM 等測試。

因此，預計在預測期內，產品發布的增加、研究合作的增加以及癌症患病率的上升將推動該細分市場的增長。

北美將佔據很大的市場份額，預計在預測期內也會如此

北美以較大的收入份額佔據市場主導地位。 促成這一細分市場佔據主導地位的因素包括心血管疾病患病率上升、產品發布增加、現有參與者的存在、技術進步和完善的醫療基礎設施。

此外，根據羅斯福大學藥學院 2020 年 9 月在 Frontiers in Immunology 上發表的題為“How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression”的研究，CRP 作為原型急性期反應物幾十年來，c-反應蛋白（c-reactive protein）的測試功能生物活性一直沒有明確定義，導致診斷學家使用 CRP 血液水平作為各種狀況和疾病持續炎症的快速指標。據說 希望此類研究將導致進一步採用 CRP 檢測來診斷體內炎症。

此外，2020 年 10 月，Nova Biomedical 為其 Allegro 毛細血管血液學分析儀推出了 CRP（C 反應蛋白）測試，用於初級保健環境中的即時 (POC) 測試。。 Allegro 及其配套儀表 StatStrip 提供 11 項臨床相關測試，以幫助臨床醫生做出治療決策和改變。 美國越來越多的 CRP 測試產品推出預計將推動這些測試的採用，並推動美國市場的增長。

因此，心血管疾病患病率上升和產品發布增加等因素預計將推動北美市場的增長。

競爭格局

C 反應蛋白檢測市場分散且競爭激烈。 主要參與者之間建立戰略夥伴關係以擴大產品組合、擴大研發、分銷和行政設施以增強市場競爭力等因素預計將推動市場增長。 該市場的公司包括雅培實驗室、丹納赫公司（貝克曼庫爾特公司）、F. Hoffmann-La Roche AG、默克公司、Quest Diagnostics、Thermo Fisher Scientific Inc. 等公司。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 炎症性疾病的患病率上升
    • 全球女性子宮內膜異位症患病率上升
    • 增加對診斷技術進步的資助
    • 越來越多地採用床旁設備
  • 市場製約因素
    • 社會意識低
    • 更準確的替代療法的可用性
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按檢測類型
    • □聯免疫吸附試驗 (ELISA)
    • 化學發光免疫分析 (CLIA)
    • 免疫比濁法
    • 其他檢測類型
  • 通過申請
    • 糖尿病
    • 類風濕性關節炎
    • 心血管疾病
    • 炎症性腸病
    • 癌症
    • 其他用途
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Zoetis（Abaxis Inc.）
    • Abbott Laboratories
    • Danaher Corporation（Beckman Coulter Inc.）
    • F. Hoffmann-La Roche AG
    • Laboratory Corporation of America Holdings
    • Merck KGaA
    • Quest Diagnostics
    • Randox Laboratories Ltd
    • Siemens Healthineers
    • Thermo Fisher Scientific Inc.
    • Getein Biotech, Inc.
    • HORIBA, Ltd
    • Boditech Med Inc.
    • Aidian

第7章 市場機會今後動向

簡介目錄
Product Code: 60431

The C-reactive protein (CRP) testing market is projected to register a CAGR of 1.8% during the forecast period (2022-2027).

COVID-19 has had an unprecedented effect on the healthcare and diagnostic industry. For instance, according to the study published in Annals of Clinical Microbiology and Antimicrobials, titled "Plasma CRP level is positively associated with the severity of COVID-19" in May 2020, plasma CRP levels were found to be linked to the severity of COVID-19 pneumonia. The findings could help distinguish mild COVID-19 pneumonia patients from those with moderate to severe COVID-19 pneumonia. This could serve as an early warning sign of serious disease, allowing doctors to better stratify patients for transfer to an intensive care unit. The importance of CRP testing in the COVID-19 infection for the stratification of patients will lead to increased demand for CRP testing, thereby impacting the market growth during the pandemic.

The major factors propelling the growth of the C-reactive protein testing market include the rise in prevalence of inflammatory disorders, diabetes, and cancers; the increasing global incidence of endometriosis in women; the rise in funding for technological advancement in diagnostics; and the rise in adoption of point-of-care devices.

According to the data published by the Center for Disease Control and Prevention and updated in July 2022, there are about 20.1 million adults aged 20 and older in United States who have coronary artery disease. It also reported that in United States, every year, about 805,000 people have a heart attack. The rising prevalence of cardiovascular diseases will lead to increased adoption of CRP testing to identify the risk associated with cardiovascular disease, thereby driving the market growth.

Furthermore, the rise in product launches of point-of-care CRP tests is expected to contribute to the growth of the CRP testing market. For instance, in May 2020, ProciseDx filed a 510k for the Procise CRP test. The test is performed utilizing ProciseDx's FRET (Fluorescent Resonance Energy Transfer) Point of Care equipment, which is an inflammatory marker extensively used in gastrointestinal therapy.

Therefore, the rising prevalence of cardiovascular disease and rising product launches for point-of-care CRP testing, among others, are expected to drive the growth of this market over the forecast period. On the other hand, lack of public awareness and the availability of alternative treatments are the factors that are expected to hinder the market's growth.

Key Market Trends

Enzyme-linked Immunosorbent Assay (ELISA) Segment is Expected to Hold a Significant Share in the Market Over the Forecast Period

The Enzyme-linked Immunosorbent Assay (ELISA) segment is expected to hold a significant share in the C-reactive protein testing market by assay type. Factors such as the rise in the prevalence of cancers; the growth in infections such as COVID-19; the surge in partnerships for the commercialization of ELISA tests; and an upsurge in product launches, among others, are expected to drive the growth of this segment during the forecast period.

According to Globocan 2020, the global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. As the ELISA test can be a useful technique for detecting cancer early on, there will be increased adoption of these tests for the detection of cancer across the world, thereby driving the segment's growth.

Furthermore, the establishment of the facilities providing the test is also expected to boost the growth of the market. For instance, in June 2021, Trivitron Healthcare launched the mobile laboratory for COVID-19 diagnostics to facilitate COVID-19 diagnostics in urban, rural, and far-flung geographies across India. The indigenous lab provides tests for CLIA/Elisa tests for inflammatory markers like D-Dimer, CRP & IL-6, RT-PCR tests, rapid antigen tests, CLIA/Elisa Antibodies Tests IgG and IgM, and others.

Therefore, rising product launches, a rise in collaborations, and a rise in the prevalence of cancer are expected to drive the growth of this segment over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

North America dominated the market with a large revenue share. The factors that are likely to be responsible for the dominance of this segment are the rise in the prevalence of cardiovascular diseases, rising product launches, the presence of established players, technological advancements, and well-established healthcare infrastructure.

In addition, according to the study published in Frontiers in Immunology, titled "How C-Reactive Protein Structural Isoforms With Distinctive Bioactivities Affect Disease Progression" in September 2020 by the Roosevelt University College of Pharmacy, United States, because of the c-reactive protein (CRP) test functional bioactivity as the prototypic acute phase reactant has eluded clear definition for decades, diagnosticians of various conditions and diseases use CRP blood levels as a simple index for ongoing inflammation. Such studies will lead to further adoption of CRP testing for the diagnosis of inflammation in the body.

Furthermore, in October 2020, Nova Biomedical launched the Allegro C-reactive protein (CRP) test for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. The Allegro and its StatStrip companion meter give 11 clinically necessary tests to assist clinicians in making therapeutic decisions and changes. The increasing product launches for CRP testing in United States will lead to increased adoption of these tests, which is thereby expected to drive the growth of this market in United States.

Therefore, the rising prevalence of cardiovascular diseases and rising product launches, among others, are the factors expected to drive the growth of this market in North America.

Competitive Landscape

The C-reactive Protein testing market is fragmented and competitive. Factors such as strategic partnerships between key market players to expand their product portfolios; expansion in research and development; distribution; and management facilities to gain a competitive edge in the market are expected to drive the market's growth. Some of the companies in this market include Abbott Laboratories, Danaher Corporation (Beckman Coulter Inc.), F. Hoffmann-La Roche AG, Merck KGaA, Quest Diagnostics, and Thermo Fisher Scientific Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Prevalence of Inflammatory Disorders
    • 4.2.2 Increasing Global Incidence of Endometriosis in Women
    • 4.2.3 Rise in Funding toward the Technological Advancement in Diagnostics
    • 4.2.4 Rise in the Adoption of Point-of-care Devices
  • 4.3 Market Restraints
    • 4.3.1 Lack of Public Awareness
    • 4.3.2 Availability of Alternative Treatments with Higher Accuracies
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Assay Type
    • 5.1.1 Enzyme-linked Immunosorbent Assay (ELISA)
    • 5.1.2 Chemiluminescence Immunoassay (CLIA)
    • 5.1.3 Immunoturbidimetric Assay
    • 5.1.4 Other Assay Types
  • 5.2 By Application
    • 5.2.1 Diabetes
    • 5.2.2 Rheumatoid Arthritis
    • 5.2.3 Cardiovascular Disease
    • 5.2.4 Inflammatory Bowel Disease
    • 5.2.5 Cancer
    • 5.2.6 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Zoetis (Abaxis Inc.)
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Danaher Corporation (Beckman Coulter Inc.)
    • 6.1.4 F. Hoffmann-La Roche AG
    • 6.1.5 Laboratory Corporation of America Holdings
    • 6.1.6 Merck KGaA
    • 6.1.7 Quest Diagnostics
    • 6.1.8 Randox Laboratories Ltd
    • 6.1.9 Siemens Healthineers
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Getein Biotech, Inc.
    • 6.1.12 HORIBA, Ltd
    • 6.1.13 Boditech Med Inc.
    • 6.1.14 Aidian

7 MARKET OPPORTUNITIES AND FUTURE TRENDS